ondasdechoque.org
PT-BR

Multiple hand and wrist disorders · Review · 2025

Can shockwave help carpal tunnel, trigger finger and other hand problems?

In this review of 44 studies, people with carpal tunnel syndrome, trigger finger and other hand and wrist problems generally reported less pain and better hand use after shockwave. In carpal tunnel syndrome, 8 of 9 studies that compared shockwave with a sham found less pain with shockwave.

Improved over time
studies in the review
44
hand and wrist conditions
5
sessions, depending on the study
1–10

Good to know: More than half of the studies were in carpal tunnel syndrome; results were not combined into one number.

Al-Mousllie I, Vogt PM, Jokuszies A GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2025 · Read the paper ↗

How this study worked

One answer
A review gathers earlier studies to answer one question. Illustration, not to scale.

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

What the trials used

Protocol ranges across included studies
Across conditions: 1–10 sessions, 500–5,000 shocks, 2–15 Hz, EFD 0.006–1.24 mJ/mm². These are heterogeneous ranges, not a recommended regimen. Authors suggest ≥5 weekly sessions for DD functional outcomes, three weekly sessions for TF, and ≥4 weekly sessions for CTS; these are cross-study interpretations, not randomized dose comparisons.

Who took part

People with Dupuytren's disease, trigger finger, De Quervain's tendon pain, Kienböck's disease of the wrist or carpal tunnel syndrome, in 44 studies from 17 countries.

Side effects

Few studies reported side effects. Those that did described mild pain during or for a day or two after sessions, short-lived redness, and swelling or numbness in a few people. The side effects the review lists were all mild.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

What the full paper reports.

Systematic qualitative review of ESWT for Dupuytren disease (DD), trigger finger (TF), De Quervain tenosynovitis (DQT), osteonecrosis of the lunate (ONL), and carpal tunnel syndrome (CTS). The authors included 44 studies from 2011–2024 across 17 countries and report a total sample over 16,623, but primary-study and review populations may overlap and unique participants are unverified.

Review scope and study characteristics9 reported outcomes
01
As reported by review; varies by included study

Review scope and study characteristics

Qualitative review synthesis Narrative synthesis

44 studies, 17 countries, 2011–2024; reported sample >16,623; protocols ranged 1–10 sessions, 500–5,000 shocks, 2–15 Hz, EFD 0.006–1.24 mJ/mm².

Analysis details and source

Underlying study-level supplementary tables were unavailable in the acquired XML; no pooled estimate or equivalence is inferred.

02
As reported by review; varies by included study

Dupuytren disease: pain and function

Qualitative review synthesis Narrative synthesis

Three studies reported improved pain/tenderness from 6 weeks through 18 months; function/symptom scores improved in 2 of 3 studies at 6–14 weeks. Grip improved in 1 of 3 studies; URAM did not change significantly in one. ESWT exceeded LIPUS in one study. No pooled estimates.

Analysis details and source

Underlying study-level supplementary tables were unavailable in the acquired XML; no pooled estimate or equivalence is inferred.

03
As reported by review; varies by included study

Trigger finger: pain, triggering and function

Qualitative review synthesis Narrative synthesis

All 6 studies reported significant within-group pain improvement; 3 of 4 studies assessing triggering reported improvement. Function benefits were reported through 6–12 months. One study favored ESWT over sham; one found no significant difference from local corticosteroid injection (LCI). Protocols ranged 1–10 sessions. Three-session “optimal” claim is cross-study inference, not randomized dose testing.

Analysis details and source

Underlying study-level supplementary tables were unavailable in the acquired XML; no pooled estimate or equivalence is inferred.

04
As reported by review; varies by included study

De Quervain tenosynovitis: pain and function

Qualitative review synthesis Narrative synthesis

Both studies reported improvements with ESWT; changes were better than sham but not significantly different from LCI. Follow-up reached 6 months. Grip strength improved in one study. Evidence grade was C; no long-term data or protocol recommendation.

Analysis details and source

Underlying study-level supplementary tables were unavailable in the acquired XML; no pooled estimate or equivalence is inferred.

05
As reported by review; varies by included study

Lunate osteonecrosis: pain, motion and imaging

Qualitative review synthesis Narrative synthesis

One study: pain and range of motion improved at 2 months versus pretreatment and did not change significantly further at 6 months or 1 year. Greatest improvement was reported in Lichtman stage I. MRI showed reduced marrow edema but no change in already necrotic bone. Authors advise no clinical implications from one study.

Analysis details and source

Underlying study-level supplementary tables were unavailable in the acquired XML; no pooled estimate or equivalence is inferred.

06
As reported by review; varies by included study

Carpal tunnel syndrome: symptoms and function

Qualitative review synthesis Narrative synthesis

All 23 primary studies reported improved symptoms; 20 of 21 assessing function reported significant improvement. Nine studies compared ESWT with sham: pain favored ESWT in 8/9 and function in 7/9. Five compared ESWT with LCI: two favored ESWT, two found no difference, one favored LCI. Four comparisons favored ESWT over physiotherapy. Six reviews were also included, which may overlap with the primary studies.

Analysis details and source

Underlying study-level supplementary tables were unavailable in the acquired XML; no pooled estimate or equivalence is inferred.

07
As reported by review; varies by included study

Subsequent surgery in CTS study

Qualitative review synthesis Narrative synthesis

One study reported surgery at 6 months in 75% receiving sham ESWT plus LCI versus 40% receiving ESWT plus LCI; review says difference was significant. This was the only one of 44 studies reporting subsequent surgery. No relative effect or uncertainty interval is available in the XML.

Analysis details and source

Underlying study-level supplementary tables were unavailable in the acquired XML; no pooled estimate or equivalence is inferred.

08
As reported by review; varies by included study

CTS electrodiagnostic measures

Qualitative review synthesis Narrative synthesis

Across 19 studies, significance varied: SNAPA 4/6, SNAPL 3/3, CMAPA 4/11, CMAPL 3/3, DSL 6/7, DML 8/12, MNCV 1/4, SNCV 9/11, CSA 4/5. These are studies reporting significant change, not pooled effects.

Analysis details and source

Underlying study-level supplementary tables were unavailable in the acquired XML; no pooled estimate or equivalence is inferred.

09
As reported by review; varies by included study

Reported adverse effects

Qualitative review synthesis Narrative synthesis

DD: one study reported mild pain for 1–2 days. DQT and ONL sections reported no adverse effects. CTS: no serious adverse effects were reported; events included mild pain during/after sessions, temporary redness, and swelling/numbness in a few patients. Reporting was sparse.

Analysis details and source

Underlying study-level supplementary tables were unavailable in the acquired XML; no pooled estimate or equivalence is inferred. The CTS section says both that no serious adverse effects were reported and that five studies “reported serious adverse effects”; the effects it then lists are slight pain during and after sessions, temporary reddening, and some swelling and numbness. They are kept as listed.

How treatment was delivered
Protocol ranges across included studies

Across conditions: 1–10 sessions, 500–5,000 shocks, 2–15 Hz, EFD 0.006–1.24 mJ/mm². These are heterogeneous ranges, not a recommended regimen. Authors suggest ≥5 weekly sessions for DD functional outcomes, three weekly sessions for TF, and ≥4 weekly sessions for CTS; these are cross-study interpretations, not randomized dose comparisons.

HARMS & TOLERABILITY

Safety reporting was sparse. DD: one study reported slight pain for 1–2 days. CTS reports included mild pain during/after sessions, temporary redness, and swelling/numbness in a few patients; authors report no serious adverse effects. DQT and ONL sections report none. This does not establish absence of harm.

LIMITS OF THE ANALYSIS

No meta-analysis was performed because of heterogeneity in designs, protocols and outcomes. Supplementary study tables, risk-of-bias assessments and search attachment were linked but not included in the acquired XML; detailed numeric results and protocols could not be checked.

One researcher conducted the search/data extraction and assessed risk of bias. Primary studies and reviews may overlap; the reported total >16,623 is not verified as unique participants.

Subsequent surgery was reported in only one of 44 included studies. The authors state the review cannot determine whether ESWT prevents surgery or only delays it.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • No meta-analysis was performed because of heterogeneity in designs, protocols and outcomes. Supplementary study tables, risk-of-bias assessments and search attachment were linked but not included in the acquired XML; detailed numeric results and protocols could not be checked.
  • One researcher conducted the search/data extraction and assessed risk of bias. Primary studies and reviews may overlap; the reported total >16,623 is not verified as unique participants.
  • Subsequent surgery was reported in only one of 44 included studies. The authors state the review cannot determine whether ESWT prevents surgery or only delays it.
Research review

Source-linked critical reading

Systematic review combining primary studies and reviews

Reading depthMaterial consulted
Technical source record

Complete main text, condition-specific findings, timepoints, comparisons, safety, risk-of-bias methods, limitations and declarations read; raw XML structure and supplementary links checked. No main-text tables; supplementary PDFs unavailable.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design

Systematic qualitative review following Cochrane and PRISMA guidance; no meta-analysis. One researcher searched, extracted and assessed risk of bias.

Evidence base

44 studies published 2011–2024 from 17 countries. The claimed total >16,623 is not verified as unique people because primary studies and reviews may overlap.

Intervention

Mixed radial and focused ESWT; across studies 1–10 sessions, 500–5,000 shocks, 2–15 Hz and EFD 0.006–1.24 mJ/mm². Detailed supplementary protocols were unavailable.

Comparators

Condition-specific sham, local corticosteroid injection (LCI), LIPUS, physiotherapy and pretreatment comparisons. Direct head-to-head evidence is limited and mixed.

Findings by condition

DD: pain improved in three studies; function was inconsistent (2/3 improved). TF: pain improved in 6/6; triggering in 3/4. DQT: both studies reported improvement. ONL: one study reported pain/ROM and MRI changes. CTS: symptoms improved in 23/23; function in 20/21. No pooled estimates.

Between-treatment evidence

In CTS, nine sham comparisons favored ESWT for pain in 8/9 and function in 7/9; LCI comparisons were mixed. In DQT, changes were better than sham but not significantly different from LCI. Nonsignificance does not establish equivalence.

Harms

Safety reporting was sparse. Reported events were generally mild, including transient pain, redness, swelling or numbness; absence of reports is not proof of safety.

Limitations

No meta-analysis; heterogeneous outcomes/protocols; one researcher performed key review tasks; supplements S1–S16 were referenced but unavailable in the acquired XML. The >16,623 total may include overlapping populations.

Applicability

Evidence is greatest in volume for CTS but remains heterogeneous. Only one study reported surgery after treatment; the review cannot establish surgery prevention.

Research needs

Make supplements accessible and map unique trials; use independent screening/extraction; conduct condition-specific controlled trials with prespecified outcomes, harms, follow-up and dose comparisons.

THE ORIGINAL SOURCE

Read the original article.

State of shock - a systematic review of extracorporeal shockwave therapy in hand surgery.

Al-Mousllie I, Vogt PM, Jokuszies A. · GMS Interdisciplinary plastic and reconstructive surgery DGPW · 2025

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →